- Home
- / TC BioPharm
- / Financials
Header placeholder lorem ipsum dolor sit amet, consectetur adipiscing elit.
TC BioPharm financials data including stock price, CreditSafe score, income statement, balance sheet, and cash flow.
Stock Price
$1.6
2024-10-29
Market Capitalization
$926.7 K
2024-10-29
CreditSafe Score
?
Score changed on Jan 23, 2025
Premium Content only available in Craft’s Intelligence Portal
View 30+ financial ratio metrics including price-to-earnings ratio, debt-to-assets ratio, gross profit margin, and more.
Financial ratio metrics help evaluate the financial strength of a company, and help raise red flags that can indicate potential risk, fulfillment challenges, or even possible bankruptcy.
Learn moreFinancial Statements
| GBP | FY, 2019 | FY, 2020 | FY, 2021 | FY, 2022 | FY, 2023 |
|---|---|---|---|---|---|
| Revenue | 3.4M | 2.0M | 2.0M | 3.8M | |
| Gross profit | 5.0M | 2.5M | 2.0M | 3.8M | |
| Gross profit margin, % | 145.6% | 128.8% | 100.3% | 100.0% | |
| Operating expense total | 10.7M | 7.8M | 8.3M | 14.8M | 13.6M |
| Depreciation and amortization | 905.0K | 1.1M | 1.0M | 966.0K | 633.0K |
| EBITDA | (5.7M) | (5.3M) | (6.3M) | (11.0M) | (13.6M) |
| EBITDA margin, % | -165.6% | -265.9% | -320.3% | -284.9% | |
| EBIT | (6.6M) | (6.3M) | (7.4M) | (12.1M) | (14.9M) |
| EBIT margin, % | -192.0% | -320.2% | -372.1% | -313.7% | |
| Interest income | 22.0K | 1.0K | |||
| Interest expense | 275.0K | 92.0K | 3.4M | 7.0M | 84.0K |
| Pre tax profit | (6.9M) | (6.4M) | (15.0M) | (3.1M) | (7.0M) |
| Income tax expense | (826.0K) | (1.2M) | (1.4M) | (1.7M) | (1.1M) |
| Net Income | (6.1M) | (5.3M) | (13.6M) | (1.4M) | (5.9M) |